Status:
COMPLETED
Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability and pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the ...
Eligibility Criteria
Inclusion
- Japanese passport holder
- Japanese-born parents
- Body mass index (BMI) between 18.0 and 27.0 kg/m\^2 (both inclusive)
- Fasting blood glucose of below or equal to 6 mmol/L
- Healthy male subjects, who are considered to be generally healthy based on an assessment of medical history, physical examination and clinical laboratory data at screening, as assessment of medical history, physical exjudged by the Investigator
Exclusion
- The receipt of any investigational drug within 3 months prior to this trial
- Subjects with a history of significant multiple drug allergies or with a known allergy to the trialproduct or any medicine chemically related to the trial product, as judged by the Investigator
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01865331
Start Date
December 1 2006
End Date
March 1 2007
Last Update
January 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuss, Germany, 41460